Lixia Guo / BuzzFeed News
ID: 10708849
Elizabeth Noble enjoyed a full and active life, and is nobodys fool. For more than a quarter-century, she taught statistics in the School of Education at the University of Missouri-Kansas City. In retirement, she continued to work as a consultant, and travelled widely in Europe and Asia.
When Noble was diagnosed with Age-Related Macular Degeneration, which slowly blurs the sharp central vision that we rely on to read, drive, and identify faces, she wanted to do something about it. And she thought she had found an answer a research study described on ClinicalTrials.gov, a website run by the National Institutes of Health (NIH), the US governments premier biomedical research agency.
It seemed scientifically legitimate, so in June 2015 Noble went to a clinic in Sunrise, Florida, where staff sucked a small quantity of fat from around her belly button, treated it with enzymes to extract the cells it contained, and mixed those cells with a sample of Nobles blood plasma. They injected the mixture into Nobles eyeballs, charged her $5,000, and told her to avoid strenuous activity for the next three days.
US Stem Cell Clinics office in Sunrise, Florida. Google Street View
ID: 10705938
Three days later, when the 72-year-old was seen by doctors at the University of Miamis Bascom Palmer Eye Institute, strenuous activity was out of the question. Nobles eyes hurt and she was nauseous. Her retinas were bleeding and she could just make out a hand being waved in front of her face.
Nobles sight continued to deteriorate and one year later she couldnt tell the difference between night and day. Thats as bad as it gets, Thomas Albini, an ophthalmologist at the Bascom Palmer Eye Institute, told BuzzFeed News, describing the condition of the woman he identified only as Patient 1.
In the latest issue of the New England Journal of Medicine, Albini and his colleagues describe the cases of three women treated by the same stem cell company, each of whom became legally blind. The doctors dont name the women involved, but BuzzFeed News established the identities of two of them from court filings and other public documents.
This isnt the first time that people have been harmed by clinics offering unproven treatments purportedly involving stem cells. In 2010, for example, a woman with the autoimmune disease lupus died after her own bone marrow cells were injected into her kidneys at a clinic in Thailand. And in 2013, the Florida Department of Health revoked the medical license of Zannos Grekos over the death of a 69-year-old woman. He had extracted material from her bone marrow, filtered it, and then infused it into the arteries feeding her brain. The woman had a stroke, and died shortly afterwards.
But the latest tragic cautionary tale has a disturbing twist, as two of the women who were blinded contacted the company involved, now called US Stem Cells but formerly known as Bioheart, only after reading about its macular degeneration study on ClinicalTrials.gov.
The site was launched in 2000 after Congress passed a law demanding that the NIH keep a registry of clinical trials experiments with new drugs on volunteer patients so that drug companies couldnt sweep negative results under the carpet. ClinicalTrials.gov has since grown to include some 290,000 studies run in countries across the globe.
But with only minimal screening of the listings, experts who track the burgeoning and loosely regulated landscape of stem cell clinics fear that the website is being abused to claim spurious legitimacy for unproven therapies that are being sold for profit.
Its very easy to register studies on ClinicalTrials.gov and essentially use a government website as a marketing device, Leigh Turner, a bioethicist at the University of Minnesota, told BuzzFeed News.
Noble told the doctors at the Bascom Palmer Eye Institute that she thought her treatment was part of a clinical trial. Patients are not usually charged to take part in research. Yet each of the three women described in the case reports were charged $5,000, and Albini said that the consent paperwork made no mention of a study.
I think it was presented as a clinical trial and documented as a fee-for-service procedure, Albini said. In September 2015, shortly after the three women were treated, the ClinicalTrials.gov listing was amended to say the study had been withdrawn prior to enrollment.
Before that change was made, it is easy to see why Noble and Patsy Bade, who also decided to seek treatment after finding the ClinicalTrials.gov listing, might have found it convincing. It includes an long list of conditions that could exclude people from participating, and indicates that patients would be studied 6 months after their treatment, to record their field of view and the sharpness of their vision.
Neither Noble nor Bade had severe sight loss before their eyeballs were injected with material extracted from their abdominal fat. Noble still had 20/30 vision in her left eye, which is barely different from normal. Its good enough to read newspaper print, Albini said. Its very functional vision. Bade, who was 78 when she was treated and lives in Venice, Florida, struggled to read fine print and had problems driving at night. But otherwise, she could function normally.
The back of Patsy Bades left eye after the stem cell treatment. Dark patches show bleeding in the retina. Thomas Albini
ID: 10705950
These ladies who were both independent were rendered blind, their attorney, Andrew Yaffa of Grossman Roth Yaffa Cohen in Coral Gables, Florida, told BuzzFeed News. The women sued US Stem Cell, the affiliated US Stem Cell Clinic, and two medical professionals who were involved in the procedures.
The suits were settled for undisclosed sums, with a confidentiality agreement that prevents Yaffa from naming the women or the company involved. Noble and Bade also told BuzzFeed News that they were not allowed to discuss their cases.
This litigation has been resolved to the mutual satisfaction of the parties, Yaffa said.
A couple of days after her injections, Bade turned up at the Bascom Palmer Eye Institute with bleeding retinas. Again, her eyesight rapidly deteriorated. A year later, she could just detect a hand waving in front of her face with her right eye, and had 20/200 vision in her left. That is the legal threshold for blindness, and means she could read an eye chart at 20 feet only as well as a person with normal vision standing 200 feet away.
Both womens eyesight would likely still be fairly good had they not been given the injections. Macular degeneration typically proceeds pretty slowly, Albini said.
Neither Mike Toms, US Stem Cells CEO, nor Kristin Comella, the companys chief science officer, returned emails and phone calls from BuzzFeed News. Comella is described on the companys website as a world renowned expert on regenerative medicine. She is not a medical doctor, and is enrolled as a PhD student in biomedical engineering at Florida International University in Miami.
Kristin Comella, US Stem Cells chief science officer, in a promotional video. youtube.com
ID: 10708284
The company responded instead with a statement from its PR firm, Becker Public Relations, which said: Since 2001, our clinics have successfully conducted more than 7,000 stem cell procedures with less than 0.01% adverse reactions reported. We are unable to comment further on specific cases due to patient confidentiality or legal confidentiality obligations. Neither US Stem Cell nor US Stem Cell Clinic currently treats eye patients.
On its website, US Stem Cell Clinic says it offers treatments for conditions from Parkinsons disease to congestive heart failure. US Stem Cells PR company would not say how many of the 7,000 procedures the company claims to have performed involved patients with eye diseases.
While the blinding of three patients is an extreme example, experts who follow the stem cell industry worry that other people may have been harmed by clinics offering unproven treatments, without their cases coming to public attention.
What Im most worried about is that this may be the tip of the iceberg, Paul Knoepfler, a stem cell biologist at the University of California, Davis, told Buzzfeed News. Last year, he and Turner of the University of Minnesota published a survey that identified 570 clinics offering unproven stem-cell treatments across the US.
Most of these clinics argue that their treatments do not need to be regulated by the Food and Drug Administration (FDA) because they are merely injecting peoples own stem cells back into their bodies. The FDA maintains that these cells count as drugs, which it must approve for clinical use, if they are more than minimally manipulated and are not replacing cells with the same basic function.
Last September, the FDA held a two-day hearing on treatments based on human cells. The FDA is evaluating the feedback we received at the hearing, along with the written comments, as we work to finalize our guidance, agency spokesperson Andrea Fischer told BuzzFeed News by email.
Its unclear whether that will to lead to a crackdown on clinics offering unproven stem-cell treatments especially as President Donald Trumps nominee for FDA commissioner, Scott Gottlieb, in 2012 co-wrote an Op-Ed for the Wall Street Journal criticizing the agencys efforts to regulate cells as drugs.
The FDA is perennially complaining to Congress that it lacks the resources to do its day job of regulating products that fall squarely in its purview, Gottlieb and his co-author wrote. Yet in chorus, the agency is always seeking novel authority to insert itself into new areas of science where its mandate is shaky.
Whatever the FDA does next, Turner argues that the NIH should do more to screen the listings posted on ClinicalTrials.gov.
The information on ClinicalTrials.gov is provided by the study sponsor or principal investigator and posting on ClinicalTrials.gov does not necessarily reflect endorsement by the NIH, Renate Myles, an NIH spokeswoman, told BuzzFeed News by email.
Earlier today, the NIH added a similarly-worded disclaimer to the website. Myles said that the change was made because of the concerns raised by Alibinis paper.
It is time NIH representatives stopped giving boilerplate responses, Turner said. They should have addressed this problem before patients were harmed.
Go here to read the rest:
These Women Went Blind After A Florida Clinic Injected Fat Cells Into Their Eyeballs - BuzzFeed News
- Breast Cancer Is Most Common Cancer In India, 1.38 Million Cases Diagnosed Annually. Know Estimated Incidence By 2030 - ABP Live - November 26th, 2023
- What Is Amyloidosis? All About The Rare Disease That Pervez Musharraf Suffered From - ABP Live - February 8th, 2023
- Autophagic death of neural stem cells mediates chronic stress-induced ... - November 7th, 2022
- Programmed cell death - Wikipedia - November 7th, 2022
- Hematopoietic Stem Cells | Hematopoiesis | Properties & Functions - September 4th, 2022
- Canadian Blood Services Stem Cells for Life - September 4th, 2022
- Devastation over death of schoolgirl, 11, who hoped she was beating cancer - Leicestershire Live - September 4th, 2022
- From optimized stem cell transplants to CAR T cell therapy: Advancing options for cancer, HIV and more - City of Hope - September 4th, 2022
- Scientists unlock the key to immortality in jellyfish - Syfy - September 4th, 2022
- Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients... - September 4th, 2022
- Menin Inhibitors Have Potential to Become the Next Class of Targeted Therapy in AML - Targeted Oncology - September 4th, 2022
- Wanted murder suspect John Belfield believed to still be in the UK as two more arrested over death of Thomas Campbell - The Manc - September 4th, 2022
- Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal... - July 8th, 2022
- Can minds persist when they are cut off from the world? - Livescience.com - July 8th, 2022
- Black Adolescent Young Adults With AML Have Worse Outcomes Vs White Population - Cancer Network - July 8th, 2022
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in... - July 8th, 2022
- How abortion ruling could affect IVF and embryonic research - The Almanac Online - July 8th, 2022
- This Morning viewers 'in tears' after boy meets donor who saved his life - Devon Live - July 8th, 2022
- Alpena detective: 'Good people out there' | News, Sports, Jobs - Alpena News - July 8th, 2022
- 'I miss my best friend': Five-year-old runs 10k to honour girl who died from rare brain tumour - Teesside Live - July 8th, 2022
- Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by... - July 8th, 2022
- Novartis AG, AstraZeneca Plc, and Pfizer Inc Among Leading Companies in the Thyroid Cancer Pipeline Products Market | Globaldata Plc - Yahoo Finance - July 8th, 2022
- A New Strategy Could Turn the Tide in Stem Cell GVHD - Medical Device and Diagnostics Industry - January 17th, 2022
- Vertex type 1 diabetes vs stem cell therapy - The Boar - January 17th, 2022
- Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT - AJMC.com Managed Markets Network - January 17th, 2022
- Nowakowski Considers CD19 Therapy in Transplant-Ineligible DLBCL - Targeted Oncology - January 17th, 2022
- Psaki demolishes Doocy with stats as he tries to claim covid now an illness of the vaccinated - newsconcerns - January 17th, 2022
- Doctors and Researchers Probe How COVID-19 Attacks the Heart - The Scientist - January 17th, 2022
- Who does donated blood that's direly needed help? - WTOP - January 17th, 2022
- Places Where Omicron is Most Contagious Eat This Not That - Eat This, Not That - January 17th, 2022
- UHN and U of T receive $24-million federal grant for transplant research - News@UofT - January 17th, 2022
- Glycyrrhizic acid ameliorates submandibular gland oxidative stress, autophagy and vascular dysfunction in rat model of type 1 diabetes | Scientific... - January 17th, 2022
- Stem cells in cancer therapy: opportunities and challenges - January 1st, 2022
- Life After Brain Death: Is the Body Still 'Alive'? | Live ... - January 1st, 2022
- Autologous Adult Stem Cells in the Treatment of Stroke | SCCAA - Dove Medical Press - January 1st, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 1st, 2022
- Cellular Therapies Fill Unmet Needs in R/R Multiple Myeloma - Targeted Oncology - January 1st, 2022
- Upregulated expression of actin-like 6A is a risk factor | CMAR - Dove Medical Press - January 1st, 2022
- COVID-19 Takes a Toll on People with Blood Cancers and Disorders - Cancer Health Treatment News - January 1st, 2022
- Mental health disorders and heart diseases - Rising Kashmir - January 1st, 2022
- Research breakthrough could mean better treatment for patients with most deadly form of brain tumor - EurekAlert - October 26th, 2021
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable... - October 26th, 2021
- European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 - Galveston County Daily News - October 26th, 2021
- Everything You Need To Know About COVID Booster Shots - Colorado Times Recorder - October 26th, 2021
- Stem cells and their role in lung transplant rejection - Michigan Medicine - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Will humans ever be immortal? - Livescience.com - October 5th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Why Bezos, Musk, Page and other billionaires want to live forever - New York Post - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - ABC 12 News - October 5th, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 5th, 2021
- Skeletons' broken clavicles tell a centuries-old tale of humans and horses - Massive Science - October 5th, 2021
- Environmental Factor - August 2021: Extramural Papers of the Month - Environmental Factor Newsletter - August 4th, 2021
- Role of traumatic brain injury in the development of glioma | JIR - Dove Medical Press - August 4th, 2021
- Targeted Therapeutics Market: Increase in Incidence of Cancer to Drive Global Market - BioSpace - August 4th, 2021
- Accumulation of Regulatory T Cells in Triple Negative Breast Cancer Ca | CMAR - Dove Medical Press - August 4th, 2021
- Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients with Multiple Myeloma - Curetoday.com - June 7th, 2021
- Autophagy suppresses the formation of hepatocyte-derived cancer-initiating ductular progenitor cells in the liver - Science Advances - June 7th, 2021
- Cancer research: New advances and innovations - Medical News Today - June 7th, 2021
- Fulvestrant Alone Found to be Superior to Venetoclax/Fulvestrant Combo in ER+/HER2- Breast Cancer - Targeted Oncology - June 7th, 2021
- Merck's KEYTRUDA Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal... - June 7th, 2021
- Stem cell study illuminates the cause of an inherited heart disorder | Penn Today - Penn Today - February 14th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with... - February 14th, 2021
- The Very First Signs of an Immune Response Have Been Filmed in a Developing Embryo - ScienceAlert - February 14th, 2021
- Arlo's Army needs stem cell donor as mum begs for help to save three-year-old's life - Glasgow Live - February 14th, 2021
- Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV (enfortumab vedotin-ejfv) in Patients with Previously... - February 14th, 2021
- [Full text] Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft | OTT - Dove Medical Press - February 14th, 2021
- The drug treatments offering the best hope of a way out of the Covid crisis - Telegraph.co.uk - February 14th, 2021
- In the war against Covid, an arsenal of drugs is on the way - Telegraph.co.uk - February 14th, 2021
- Kat Wests husband, Jeff West, sentenced to 16 years in wifes death - AL.com - February 9th, 2021
- Harnessing the Potential of Cell and Gene Therapy - OncLive - February 9th, 2021
- I Survived Cancer, and Then I Needed to Remember How to Live - The Atlantic - February 9th, 2021
- [Full text] Higher Red Blood Cell Distribution Width is a Poor Prognostic Factor f | CMAR - Dove Medical Press - February 9th, 2021
- West Belfast woman to be remembered in special TV documentary - Belfast Live - January 29th, 2021
- UTV documentary tells of young Belfast woman's lasting legacy to promote stem cell donation - The Irish News - January 29th, 2021
- L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL - Targeted Oncology - January 29th, 2021
- Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes... - January 29th, 2021
- If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? - Kaiser Health News - January 29th, 2021
- Experimental taphonomy of organelles and the fossil record of early eukaryote evolution - Science Advances - January 29th, 2021